The 7 major bronchitis markets reached a value of US$ 4.4 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 5.7 Billion by 2034, exhibiting a growth rate (CAGR) of 2.92% during 2023-2034.
The bronchitis market has been comprehensively analyzed in this report titled "Bronchitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bronchitis is an illness that occurs when the airways in the lungs, referred to as bronchial tubes, become inflamed and produce coughing, typically with mucus production. Depending on the duration of the disease, bronchitis is classified as acute or chronic. The common symptoms of this ailment include respiratory problems like chest congestion, coughing with mucus that's clear, yellow, white, or green in color, shortness of breath, fatigue, wheezing, or a whistling sound while breathing. In some cases of acute bronchitis, individuals may additionally experience body aches and chills, low fever, runny or stuffy nose, sore throat, etc. The diagnosis of this condition is typically made by reviewing the patient's medical history, lifestyle choices, and clinical features. Numerous other frequent investigations utilized to confirm a diagnosis include physical examinations, blood workups, pulmonary function tests, sputum tests, etc. The healthcare professional may also perform chest X-rays to detect the possible cause of disease indications among patients.
The increasing cases of bacterial and viral infections, which can irritate the bronchial tubes and cause airway inflammation, are primarily driving the bronchitis market. Apart from this, the rising incidences of respiratory disorders caused by exposure to hazardous materials, such as chemical fumes and dust, high levels of air pollution, smoking, etc., are also bolstering the market growth. Furthermore, the widespread adoption of effective drugs, including antibiotics, bronchodilators, anti-inflammatories, etc., that can open airways within the lungs and aid symptom relief among patients is creating a positive outlook for the market. Besides this, the escalating utilization of bronchial rheoplasty, which involves the application of nonthermal pulsed electrical fields to ablate the abnormal mucus-producing cells and promote healthy regeneration of the airway epithelium, is also augmenting the market growth. Additionally, numerous key players are making extensive investments in research activities to innovate novel diagnostic tools for the early detection and better monitoring of the disease. This, in turn, is acting as another significant growth-inducing factor. Moreover, the emerging popularity of targeted lung denervation technique that aims to improve airflow blockages by disrupting the parasympathetic pulmonary nerves and decreasing the release of acetylcholine is expected to drive the bronchitis market in the coming years.
This report provides an exhaustive analysis of the bronchitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bronchitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bronchitis market in any manner.
The bronchitis market has been comprehensively analyzed in this report titled "Bronchitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bronchitis is an illness that occurs when the airways in the lungs, referred to as bronchial tubes, become inflamed and produce coughing, typically with mucus production. Depending on the duration of the disease, bronchitis is classified as acute or chronic. The common symptoms of this ailment include respiratory problems like chest congestion, coughing with mucus that's clear, yellow, white, or green in color, shortness of breath, fatigue, wheezing, or a whistling sound while breathing. In some cases of acute bronchitis, individuals may additionally experience body aches and chills, low fever, runny or stuffy nose, sore throat, etc. The diagnosis of this condition is typically made by reviewing the patient's medical history, lifestyle choices, and clinical features. Numerous other frequent investigations utilized to confirm a diagnosis include physical examinations, blood workups, pulmonary function tests, sputum tests, etc. The healthcare professional may also perform chest X-rays to detect the possible cause of disease indications among patients.
The increasing cases of bacterial and viral infections, which can irritate the bronchial tubes and cause airway inflammation, are primarily driving the bronchitis market. Apart from this, the rising incidences of respiratory disorders caused by exposure to hazardous materials, such as chemical fumes and dust, high levels of air pollution, smoking, etc., are also bolstering the market growth. Furthermore, the widespread adoption of effective drugs, including antibiotics, bronchodilators, anti-inflammatories, etc., that can open airways within the lungs and aid symptom relief among patients is creating a positive outlook for the market. Besides this, the escalating utilization of bronchial rheoplasty, which involves the application of nonthermal pulsed electrical fields to ablate the abnormal mucus-producing cells and promote healthy regeneration of the airway epithelium, is also augmenting the market growth. Additionally, numerous key players are making extensive investments in research activities to innovate novel diagnostic tools for the early detection and better monitoring of the disease. This, in turn, is acting as another significant growth-inducing factor. Moreover, the emerging popularity of targeted lung denervation technique that aims to improve airflow blockages by disrupting the parasympathetic pulmonary nerves and decreasing the release of acetylcholine is expected to drive the bronchitis market in the coming years.
This report provides an exhaustive analysis of the bronchitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bronchitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bronchitis market in any manner.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the bronchitis market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the bronchitis market
Competitive Landscape:
This report also provides a detailed analysis of the current bronchitis marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the bronchitis market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the bronchitis market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the bronchitis market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of bronchitis across the seven major markets?
- What is the number of prevalent cases (2018-2034) of bronchitis by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of bronchitis by gender across the seven major markets?
- What is the number of prevalent cases (2018-2034) of bronchitis by type across the seven major markets?
- How many patients are diagnosed (2018-2034) with bronchitis across the seven major markets?
- What is the size of the bronchitis patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of bronchitis?
- What will be the growth rate of patients across the seven major markets?
Bronchitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for bronchitis drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bronchitis market?
- What are the key regulatory events related to the bronchitis market?
- What is the structure of clinical trial landscape by status related to the bronchitis market?
- What is the structure of clinical trial landscape by phase related to the bronchitis market?
- What is the structure of clinical trial landscape by route of administration related to the bronchitis market?
Table of Contents
1 Preface3 Executive Summary6 Patient Journey9 Bronchitis - Unmet Needs10 Bronchitis - Key Endpoints of Treatment13. Bronchitis - Attribute Analysis of Key Marketed and Pipeline Drugs16 Bronchitis - Recent Events and Inputs From Key Opinion Leaders18 Bronchitis Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Bronchitis - Introduction
5 Bronchitis - Disease Overview
7 Bronchitis - Epidemiology and Patient Population
8 Bronchitis - Treatment Algorithm, Guidelines, and Medical Practices
11 Bronchitis - Marketed Products
12 Bronchitis - Pipeline Drugs
14. Bronchitis - Clinical Trial Landscape
15 Bronchitis - Market Scenario
17 Bronchitis Market - SWOT Analysis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 135 |
| Published | May 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 4.4 Billion |
| Forecasted Market Value ( USD | $ 5.7 Billion |
| Compound Annual Growth Rate | 2.4% |
| Regions Covered | Global |
